Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01638546 | Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer | active not recruiting | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT02344355 | A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme | active not recruiting | Phase 2 | 90 | Bryan AllenOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT02883062 |
| Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer |
| active not recruiting |
| Phase 2 |
| 67 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Sep 30, 2026 |
| clinicaltrials |
| NCT03278782 | Study of Pembrolizumab (MK-3475) in Combination With Romidepsin | active not recruiting | Phase 1 / Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT03348631 | Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer | active not recruiting | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT03373097 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 42 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT03448835 | Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)(PANDA) | active not recruiting | Phase 2 | 20 | The Netherlands Cancer InstituteOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT03478514 | Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma | active not recruiting | Phase 2 | 39 | Alliance Foundation Trials, LLC.OTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT04017455 | Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)(TARZAN) | active not recruiting | Phase 2 | 38 | The Netherlands Cancer InstituteOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT04560322 | Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL | active not recruiting | Phase 2 | 40 | Massachusetts General HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT04733534 | An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer | active not recruiting | Phase 2 | 120 | St. Jude Children's Research HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT04989946 | Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | University of Wisconsin, MadisonOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05370807 | A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma(RegoMel) | active not recruiting | Phase 2 | 48 | Universitair Ziekenhuis BrusselOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06081673 | Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC | active not recruiting | Phase 2 | 72 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06206837 | A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. | active not recruiting | Phase 1 / Phase 2 | 71 | PfizerINDUSTRY | 8 | Sep 30, 2026 | clinicaltrials |
| NCT06305247 | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 36 | IpsenINDUSTRY | 3 | Sep 30, 2026 | clinicaltrials |
| NCT06376136 | A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors | active not recruiting | Phase 1 / Phase 2 | 218 | Bio-Thera SolutionsINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06833008 | A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 42 | IpsenINDUSTRY | 4 | Sep 30, 2026 | clinicaltrials |
| NCT07143604 | A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2(GAMBIT) | active not recruiting | Phase 2 | 33 | AstraZenecaINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT00496522 | Proton Beam Therapy for Chondrosarcoma | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01758445 | Proton Radiation for Stage II/III Breast Cancer | active not recruiting | Phase 2 | 220 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01770418 | A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 32 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01896999 | Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 146 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT02345265 | Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | active not recruiting | Phase 2 | 6,452 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT02502266 | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | active not recruiting | Phase 2 / Phase 3 | 582 | National Cancer Institute (NCI)NIH | 5 | Sep 29, 2026 | clinicaltrials |
| NCT03059485 | DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission | active not recruiting | Phase 2 | 82 | Beth Israel Deaconess Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03597321 | Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML(ELIT-AML01) | active not recruiting | Phase 2 | 124 | Institut Paoli-CalmettesOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03598257 | Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer | active not recruiting | Phase 2 | 300 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT03707808 | Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, AS01B, and Ipilimumab Plus Systemic Nivolumab(myDAvIpNi) | active not recruiting | Phase 1 / Phase 2 | 18 | Universitair Ziekenhuis BrusselOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03837899 | Durvalumab and Tremelimumab for Pediatric Malignancies | active not recruiting | Phase 1 / Phase 2 | 50 | AstraZenecaINDUSTRY | 7 | Sep 29, 2026 | clinicaltrials |
| NCT03971461 | Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma | active not recruiting | Phase 2 | 32 | NYU Langone HealthOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04175912 | Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04310007 | Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 117 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04396821 | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 150 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04495296 | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 320 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04548752 | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | active not recruiting | Phase 2 | 88 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04605913 | Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC | active not recruiting | Phase 1 / Phase 2 | 40 | Mayo ClinicOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04708418 | A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma | active not recruiting | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04751370 | Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer | active not recruiting | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05081193 | Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer | active not recruiting | Phase 2 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05322590 | BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma(ASIST) | active not recruiting | Phase 1 / Phase 2 | 195 | Bexion Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05354557 | Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) | active not recruiting | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05685004 | Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) | active not recruiting | Phase 2 / Phase 3 | 120 | TVAX BiomedicalINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05731271 | A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 111 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05768711 | Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)(AVENHIR) | active not recruiting | Phase 2 | 44 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05845671 | Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations | active not recruiting | Phase 1 / Phase 2 | 12 | University of Colorado, DenverOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05864534 | Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 25 | Northwestern UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05871021 | Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma(PRIDE) | active not recruiting | Phase 2 | 107 | University Hospital TuebingenOTHER | 1 | Sep 29, 2026 | clinicaltrials |
Data updated 29 minutes agoSource updated Sep 30, 2026source: clinicaltrials